Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort

NCT02516592 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: QVA149 110/50 micrograms
DRUG: Salmeterol/fluticasone 50/500 microgrammes

Sponsor

Novartis Pharmaceuticals